Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
gptkb:910463-68-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developer |
gptkb:Pfizer
|
| gptkbp:drugClass |
fatty acid amide hydrolase inhibitor
|
| gptkbp:hasInChIKey |
QJQYJZVZKZVQJH-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C23H20F3N3O2
|
| gptkbp:hasTherapeuticUse |
osteoarthritis
pain |
| https://www.w3.org/2000/01/rdf-schema#label |
910463-68-2
|
| gptkbp:IUPACName |
4-[2-(3-cyanopyridin-2-yl)-1,3-dioxoisoindolin-5-yl]-N-(2,2,2-trifluoroethyl)piperazine-1-carboxamide
|
| gptkbp:molecularWeight |
427.42 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154816 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:PF-04457845
|
| gptkbp:bfsParent |
gptkb:Ozempic
gptkb:semaglutide |
| gptkbp:bfsLayer |
7
|